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The gene(s) whose expression is regulated by allergy risk variants is unknown for many loci identified through genome-wide association
studies. Addressing this knowledge gap might point to new therapeutic targets for allergic disease. The aim of this study was to identify
the target gene(s) and the functional variant(s) underlying the association between rs7009110 on chromosome 8q21 and allergies. Eight
genes are located within 1 Mb of rs7009110. Multivariate association analysis of publicly available exon expression levels from lympho-
blastoid cell lines (LCLs) identified a significant association between rs7009110 and the expression of a single gene, PAG1 (p ¼ 0.0017),
732 kb away. Analysis of histone modifications and DNase I hypersensitive sites in LCLs identified four putative regulatory elements
(PREs) in the region. Chromosome conformation capture confirmed that two PREs interacted with the PAG1 promoter, one in allele-
specific fashion. To determine whether these PREs were functional, LCLs were transfected with PAG1 promoter-driven luciferase reporter
constructs. PRE3 acted as a transcriptional enhancer for PAG1 exclusively when it carried the rs2370615:C allergy predisposing allele, a
variant in complete linkage disequilibriumwith rs7009110. As such, rs2370615, which overlaps RelA transcription factor (TF) binding in
LCLs and was found to disrupt Foxo3a binding to PRE3, represents the putative functional variant in this locus. Our studies suggest
that the risk-associated allele of rs2370615 predisposes to allergic disease by increasing PAG1 expression, which might promote B cell
activation and have a pro-inflammatory effect. Inhibition of PAG1 expression or function might have therapeutic potential for allergic
diseases.To date, genome-wide association studies (GWASs) have
identified 41 genetic associations with allergic diseases
(Table S1), including asthma (MIM: 600807), hay fever or
allergic rhinitis (MIM: 607154), and atopic dermatitis or
eczema (MIM: 603165). The identification of allergy risk
variants is expected to provide new insights into the mo-
lecular pathways involved in disease pathophysiology
and, in this way, facilitate the development of new disease
treatments. However, these expectations have been hard to
meet and this represents a major bottleneck in the field.
There are two main reasons for this. First, for many loci,
there is no functional evidence linking the risk variant
with changes in the expression or protein sequence of
any nearby genes; the likely target gene(s) is therefore un-
known. This is the case for 27 of the 41 allergy risk loci
discovered to date; of note, for 10 of these 27 loci, experi-
mental mouse models of allergic disease implicate nearby
genes in disease pathophysiology. Second, often there is
little or no information available to determine whether
and how disruption of the expression or sequence of the
target gene impacts cellular function and, ultimately, dis-
ease pathophysiology. Addressing these knowledge gaps
is critical to help translate GWAS findings into clinically
useful information.
In a recent GWAS, we compared 6,685 individuals with
both asthma and hay fever against 14,091 control subjects
free of asthma and hay fever and identified two new
risk loci for allergic disease: 8q21 and 16p13.1 Variants in1QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia
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The Amerboth were associated with the individual risks of asthma
and hay fever, but the association was stronger with
the combined asthma and hay fever phenotype. In the
16p13 locus, evidence from gene expression studies sug-
gests that DEXI is the most likely target gene of this associ-
ation;2,3 functional studies of this gene are now warranted
to understand how variation in its expression might affect
disease risk. Currently, the gene whose expression is regu-
lated by allergy risk variants in the 8q21 locus is unknown.
Therefore, the aim of this study was to use both population
genetics and functional approaches to identify the target
gene(s) and likely causal variant(s) underlying the 8q21 as-
sociation with allergy risk. The study procedures used were
approved by the Human Research Ethics Committee from
the QIMR Berghofer Medical Research Institute.
Eight genes and one miRNA are located within 1 Mb of
the sentinel SNP rs7009110, which has a 36% risk allele fre-
quency in Europeans and was associated with a 1.14 per-
allele odds of disease,1 the nearest gene being ZBTB10
(Figure 1A). rs7009110 was the variant with the strongest
association with disease risk after imputation of unmea-
sured variants from the 1000 Genomes Project.1 Forty-
three gene expression quantitative trait loci (eQTLs) have
been reported in this 2 Mb region across six relevant tissue
or cell types, but rs7009110 is not in linkage disequilibrium
(LD) with any of these (Table S2). However, rs7009110 is in
modest LD with two nearby risk variants associated with
eczema (rs7000782, r2 ¼ 0.51)4 and rheumatoid arthritis@qimrberghofer.edu.au (M.A.R.F.)
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Figure 1. Allergy Risk SNPs Are Associ-
ated with PAG1 Expression and Overlap
Putative Regulatory Elements
(A) Location of the core region of associa-
tion (blue rectangle) and genes located
within 1 Mb of the GWAS sentinel SNP,
rs7009110.
(B) Results from multivariate association
analysis (n ¼ 373) between exon expres-
sion levels and variants in the core
region of association. The color of each
variant reflects linkage disequilibrium
with rs7009110 (purple square).
(C) Location of four PREs, based on histone
marks and DNase I hypersensitive sites in
an LCL analyzed by the ENCODE project.
(D) Location of the 3C interacting frag-
ments, the two fragments cloned in the
luciferase assays, and the SNPs that are in
LD (r2 > 0.6) with rs7009110 and overlap
the cloned fragments.(MIM: 180300; rs998731, r2¼ 0.20);5 in Europeans, the risk
alleles for these three variants (rs7009110:T, rs7000782:A,
and rs998731:T) are on the same haplotype. The associa-
tions at this locus with asthma, hay fever, eczema, and
rheumatoid arthritis suggest that the underlying disrup-
ted molecular mechanism affects a component of the
immune system that is shared between allergic and
auto-immune diseases. The most plausible candidate
target genes are TPD52 (MIM: 604068), which is involved
in B cell maturation;6 PAG1 (MIM: 605767), involved in T
and B cell activation;7–10 and ZBTB10, a putative repressor
of the Sp1 transcription factor (TF),11 which regulates
multiple immune-related genes.12,13
We first considered the possibility that the lack of a pub-
lished association between rs7009110 and the expression
of nearby genes could represent a false-negative finding,
arising because (1) a true association did not exceed the
false discovery rate threshold in the original eQTL studies
and so was not reported; and/or (2) most published
eQTL studies surveyed used expression microarrays, which330 The American Journal of Human Genetics 97, 329–336, August 6, 2015have incomplete coverage of gene
expression patterns. To test this
possibility, we analyzed RNA-seq
data obtained by the Geuvadis Proj-
ect14 for lymphoblastoid cell line
(LCL) samples of 373 individuals of
European descent from the 1000
Genomes Project.15 LCLs are derived
from peripheral blood B cells and
therefore represent a practical and
effective in vitro model to study
gene expression patterns relevant to
immune-related conditions.
Genotype and RNA-seq data were
downloaded from EBI ArrayExpress:
E-GEUV-1 and E-GEUV-2. As in
Lappalainen,14 we selected the exon(not the gene) as the quantification unit and restricted
the analysis to exons expressed in >90% of all the individ-
uals. Read counts normalized by library depth and with
technical variation removed by PEER normalization14
were available for all exons of six of the eight genes located
within a 1 Mb region around rs7009110. Read counts were
quantile normalized and adjusted for ancestry informative
covariates and genotype imputation status, as in Lappalai-
nen.14 For each of these six genes, the association between
rs7009110 allelic dosage and variation in the expression of
all exons was tested simultaneously via a multivariate test
of association that improves power over the alternative
strategy of testing each exon individually.16 The remaining
two genes, ZNF704 and STMN2 (MIM: 600621), were ex-
pressed in only 56% and 12% of samples, respectively.
Given their low relative abundance and because there
was no association between dichotomized read counts
(expressed versus not expressed) and rs7009110 geno-
type (not shown), both genes were excluded from further
analysis. Likewise, the expression of miR5708 was not
associated with rs7009110 (not shown) and so this miRNA
was not considered further.
Multivariate association was tested between rs7009110
and the expression levels of five exons in each of HEY1
(MIM: 602953), MRPS28 (MIM: 611990), and FABP5
(MIM: 605168); seven in ZBTB10; nine in PAG1; and ten
in TPD52. In this analysis, rs7009110 was significantly
associated with the expression of PAG1 (p ¼ 0.0017) but
with no other gene (Table S3). The weights attributed to in-
dividual PAG1 exons in the multivariate analysis were
consistent with an effect of rs7009110 on the expression
of exons 1, 2, and 3; this observation was confirmed with
individual univariate analyses of these three exons (Table
S4). The rs7009110:T allele that increases the risk of
allergic disease was associated with an increased expres-
sion of PAG1 (Figure S1), explaining 2.6% of the observed
variation.
To help fine-map the eQTL results for PAG1, we extended
the multivariate association analysis to an additional 167
common variants (MAF R 5%, call rate > 95%, Hardy-
Weinberg equilibrium test p value > 106) located in the
69.4 kb core region of association with allergic disease, de-
limited by the left-most (rs7822328, chr8: 81,246,659) and
right-most (rs4739746, chr8: 81,316,034) variants in LD
(r2 R 0.6) with rs7009110. This is the region most likely
to include the underlying causal variant(s); most variants
were in LD with rs7009110 (70% with r2 R 0.6). Multiple
SNPs in high LD (r2R 0.8) with rs7009110 were associated
with the expression of PAG1 (Figure 1B). In general, the
strength of the association increased with the physical
proximity to rs7009110 but did not exceed that seen
with this SNP. However, no SNPs in LD (r2 R 0.6) with
rs7009110 showed an association with the expression of
the other five genes tested (p > 0.05, Figure S2).
Although the association between 8q21 allergy risk vari-
ants and PAG1 expression in LCLs was relatively modest, it
pointed to the possibility that a regulatory element in this
regionmight control the expression of PAG1. Thus, wenext
queried genome-wide maps of epigenetic profiles to search
for putative regulatory elements (PREs) in the 8q21 core
region of association. Analysis of histone modifications
associated with regulatory activity (e.g., H3K4me1/2) and
DNase I hypersensitive sites assayed by the ENCODE
Project17 in an LCL (GM12878) identified four PREs in
this region, named PRE1 to PRE4 (Figure 1C). Consistent
with these results, Seumois et al.18 detected a significant
gain in H3K4me2, which marks both active and poised
enhancers, in PRE1 and PRE2when comparing primary hu-
manCD4þmemory Tcells against naive CD4þ Tcells. Simi-
larly, Hnisz et al.19 predicted PRE3 to be an enhancer in
multiple human immune cell types. Of the 118 SNPs that
are in LD (r2 R 0.6) with rs7009110, 35 overlap one of
the four PREs identified (Table S5); rs7009110 overlaps
PRE3. We therefore hypothesized that (1) one (or more)
of these four PREs in this region regulates the expression
of PAG1 and (2) rs7009110 or a correlated variant disrupts
the function of the PRE.The AmerTo test the first hypothesis, we used Chromosome
Conformation Capture (3C) as described previously20 to
quantify the frequency of long-range chromatin interac-
tions that take place between the core region of association
and the promoter of PAG1, 710 kb apart. In brief, 3C li-
braries were created by cross-linking the chromatin from
LCLs of individuals homozygous for the rs7009110:T risk
allele (n ¼ 2) or the C protective allele (n ¼ 2); DNA was
then digested with EcoRI, which flanks 17 contiguous frag-
ments that cover the core region of association, as well as
the PAG1 promoter (Table S6); DNA was religated and de-
crosslinked; and quantitative PCR (qPCR) with primers
for the bait (PAG1 promoter) and interactors (17 frag-
ments) was then performed to detect the presence of liga-
tion products, which represent gene loops. BAC clones
covering the regions of interest were used to normalize
for PCR efficiency.
The frequency of chromatin interactions between the
PAG1 promoter and 15 of the 17 fragments that covered
the core region of association was low and consistent
with being due to chance (Figure 2A). However, for two
fragments—numbered F9 and F11—the interaction fre-
quency was significantly above the background level.
The size of the interaction products amplified was
confirmed by gel electrophoresis and their sequence veri-
fied by Sanger sequencing; similar results were also ob-
tained in two additional independent replicates of each
sample (Figure S3). Fragment F9 is 1.1 kb long and overlaps
the centromeric end of PRE2, including the peak region of
H3K4me2 gain observed by Seumois et al.18 in memory
CD4þ T cells. Interactions with fragment F9 were observed
in LCLs homozygote for the rs7009110:C protective allele
but not (or less frequently) for the T predisposing allele.
Consistent with this, allele-specific 3C from two LCLs het-
erozygous for rs11783496, a SNP near fragment F9 and in
LD with rs7009110 (r2 ¼ 0.75), indicate that the protective
C allele of rs11783496 is more strongly associated with
looping of PRE2 to the PAG1 promoter (Figures 2B and
S4). These results suggest that an allergy protective allele
(rs11783496:C or another on the same haplotype) is
associated with the establishment of long-range chromatin
interactions between PRE2 and the PAG1 promoter.
The interaction observed with fragment F11—which is
10.6 kb long and overlaps both the telomeric end of
PRE2 and the centromeric end of PRE3—was detected in
all four samples, irrespective of rs7009110 genotype. This
suggests that allergy-associated variants do not influence
the establishment of chromatin looping between the
PAG1 promoter and PRE3.
Having established that two independent DNA frag-
ments overlapping PRE2 and PRE3 physically interact
with the promoter of PAG1, next we tested the hypothesis
that the regulatory ability of these two PREs is modulated
by allergy risk variants. To assess this, a PAG1 promoter-
driven luciferase reporter construct was generated by in-
serting a 1,660 bp fragment containing the PAG1 promoter
into pGL3-basic, as described previously.21 A fragmentican Journal of Human Genetics 97, 329–336, August 6, 2015 331
Figure 2. Chromatin Interactions at the
8q21 Risk Region with PAG1
(A) 3C interaction profiles indicating
frequent interactions between PRE2 and
PRE3 and the PAG1 promoter region. 3C li-
braries were generated with EcoRI, with
the anchor point set at the PAG1 promoter.
A physical map of the region interrogated
by 3C is shown below, with the blue bars
representing the position of the PREs and
the black lines representing the EcoRI frag-
ments interrogated. Triangles show posi-
tion of variants in linkage disequilibrium
(LD) with rs7009110, with color gradient
representing the strength of association
with PAG1 expression levels (cf. Figure 1B),
from most associated in red to least associ-
ated in gray.Graph shows3Cprofiles gener-
ated from four different LCLs assayed in
duplicate. Error bars denote SD.
(B) Allele-specific chromatin looping between PRE2 and the PAG1 promoter. 3C followed by direct sequencing of the PCR product was
performed in two heterozygous LCLs with rs11783496 as the surrogate marker. The rs11783496:C and rs7009110:C alleles are in phase
(r2 ¼ 0.75). Chromatograms represent one of two independent 3C libraries generated and sequenced.overlapping PRE2 (1,893 bp) or PRE3 (1,560 bp) and con-
taining the major (i.e., allergy protective) allele for SNPs
in LD (r2 > 0.6) with rs7009110 was inserted downstream
of luciferase. The coordinates of these fragments were
selected such that they coincided with the two interaction
peaks observed in the 3C experiments (fragments F9 and
F11) and, within these regions, with the highest density
of histone modifications and DNase I hypersensitive sites
from ENCODE (Figures 1D and S5). To assess the effect
of individual SNPs on PRE activity, the minor (i.e., allergy
predisposing) allele for SNPs in LD with rs7009110
was individually incorporated into PRE2 (rs11783496,
rs11786685, rs11786704, or rs13275449) and PRE3
(rs4739737, rs10957979, or rs2370615) (Figure 1D) via
standard DNA cloning. All constructs were sequenced to
confirm variant incorporation (AGRF). Primers used to
generate all constructs are listed in Table S7. LCLs were
electroporated with the reporter plasmids and luciferase ac-
tivity was measured 24 hr post-transfection. To correct for
any differences in transfection efficiency or cell lysate
preparation, Firefly luciferase activity was normalized to
Renilla luciferase. The activity of each test construct was
calculated relative to PAG1 promoter construct.
Our 3C studies provided evidence for allele-specific chro-
matin looping between PRE2 and PAG1. Despite this, PRE2
did not enhance or silence the PAG1 promoter in reporter
assays (Figure 3A), making it unclear of the functional
consequence of allele-specific chromatin looping. For
PRE3, which interacted with the PAG1 promoter irrespec-
tive of genotype, we found that the construct containing
the major (allergy protective) allele at the three SNPs
(rs4739737, rs10957979, and rs2370615) in LD with
rs7009110 also did not increase PAG1 promoter activity
(Figure 3B). A similar lack of regulatory activity was
observed for PRE3 when the fragments cloned contained
the minor (allergy predisposing) allele for rs4739737 or
rs10957979. However, the PRE3 construct containing the332 The American Journal of Human Genetics 97, 329–336, August 6minor allele for rs2370615 increased PAG1 promoter activ-
ity by 1.8-fold when compared to the promoter-only
construct (p ¼ 0.0051) and by 2.3-fold when compared
to the construct with the promoter plus the enhancer
containing the major alleles (p ¼ 0.0005). These results
demonstrate that PRE3 acts as a transcriptional enhancer
in the presence of the rs2370615:C allergy predisposing
allele. Consistent with this effect, rs2370615:C was associ-
ated with increased expression of PAG1 in the eQTL
analyses described above (p ¼ 0.0018); this variant is in
complete LD (r2¼ 1) with rs7009110. Collectively, these re-
sults confirm that PAG1 is a target gene of 8q21 allergy risk
variants and suggest that rs2370615 represents the under-
lying putative functional variant.
Based on ENCODE ChIP-seq data for LCLs,17 two
transcription factors (TFs) bind to PRE3 and overlap the
putative functional variant rs2370615: the RelA (or p65
[MIM: 164014]) subunit of the nuclear factor kB (NF-kB)
TF, which is critical for innate and adaptive immune re-
sponses,22 and the POU domain class 2 transcription factor
2 (POU2F2 or Oct-2 [MIM: 164176]), which regulates
B-cell-specific genes.23 These TFs have been shown to co-
occur in LCLs24 and to synergistically regulate enhancer
activity in B cells.25 Furthermore, TNF-a (MIM: 191160)-
induced recruitment of RelA to enhancers involved in
long-range looping interactions is associated with tran-
scriptional induction of target genes.26 These observations
suggest that binding of RelA and Oct-2 to PRE3 might be
required for long-range activation of PAG1 transcription.
However, despite RelA binding to PRE3 being highest pre-
cisely over rs2370615 (Figure S5), this T/C polymorphism
is not predicted to disrupt the binding motifs reported
for either RelA or Oct-2.24,27 Based on these observations,
it is possible that the rs2370615:C allele alters the binding
affinity of another transcription factor, which is involved
in RelA recruitment to PRE3 and so promotes long-range
activation of PAG1 transcription., 2015
Figure 3. PRE3 Containing the rs2370615 Risk Allele Acts as an
Enhancer on the PAG1 Promoter
PRE2 (A) or PRE3 (B) was cloned upstream of a PAG1 promoter-
driven luciferase reporter with and without the candidate causal
SNPs. 1 mg of each plasmid was electroporated into 1 3 106 cells
with Amaxa NucleofectorII with the SF buffer and the program
EH-100. Luciferase activity was measured after 24 hr via the
Dual-Glo luciferase assay system on a Beckman-Coulter DTX-800
plate reader. Graphs represent three independent experiments as-
sayed in duplicate. Error bars denote 95% CI and p values were
determined with a two-way ANOVA followed by Dunnett’s multi-
ple comparisons test (*p < 0.01, **p < 0.001).Notably, the rs2370615:C allele is predicted to disrupt
the binding motif (TTGTTTAC) for five Forkhead box
(Fox) TFs,28 namely Foxo3a (MIM: 602681), an NF-kB
antagonist that inhibits lymphocyte activation and prolif-
eration.29 To test this prediction, we performed chromatin
immunoprecipitation (ChIP) using an anti-Foxo3a rabbit
mAb (2497S, Cell Signaling Technology) to determine
Foxo3a binding to the PRE3 region that overlaps
rs2370615 (Table S8), in LCLs with the rs2370615:TT, CT,
or CC genotype. When compared to an IgG control anti-
body (SC-8334, Santa Cruz Biotechnology), we observed
a significant enrichment in Foxo3a binding to PRE3 for
the TT (3.4-fold, p ¼ 0.001) and TC (1.3-fold, p ¼ 0.006)
but not CC (0.94-fold, p ¼ 0.820) LCLs (Figure 4A). Differ-
ences in IgG-normalized Foxo3a binding to PRE3 were
statistically significant when comparing TT to either theThe AmerTC (p ¼ 0.0018) or CC (p ¼ 0.0003) LCLs. This pattern of
Foxo3a binding was not observed in a control region 4
kb upstream of PRE3 that does not contain the canonical
Fox binding motif (Table S8). Although there was a slight
enrichment of Foxo3a binding across the three LCLs in
this region (Figure 4B), suggesting that Foxo3a might
bind weakly to it, there were no significant differences be-
tween genotypes after correction for multiple testing.
These results confirm that Foxo3a binds with high affinity
to the PRE3 region that overlaps rs2370615 and that the
C allele of this polymorphism reduces Foxo3a binding
to PRE3.
Lastly, given that Foxo3a was confirmed to bind to PRE3,
which regulates PAG1 expression, we hypothesized that
FOXO3A expression in LCLs might be correlated with
PAG1 expression. To test this hypothesis, we used gene-
expression results for LCLs of 373 individuals obtained
by the Geuvadis Project,14 as described above, to measure
the association between FOXO3A and PAG1 (exon 2)
expression, stratified by rs2370615 genotype (Figure 5).
There was a significant positive correlation between
FOXO3A and PAG1 expression in TT (r ¼ 0.31, 95% CI
0.15–0.45, p ¼ 0.0003) and TC (r ¼ 0.21, 95% CI 0.06–
0.34, p ¼ 0.0055) but not CC (r ¼ 0.12, 95% CI 0.37–
0.15, p ¼ 0.3960) LCLs, consistent with the disruptive
effect of the rs2370615:C allele on Foxo3a binding to
PRE3. This interaction effect between FOXO3A levels and
rs2370615 genotype on PAG1 expression was statistically
significant (p ¼ 0.0157).
Collectively, our results are consistent with a model
that includes the following. (1) PRE3 is a poised regulatory
element for PAG1 in all individuals, irrespective of
genotype, and promotes PAG1 transcription. (2) PRE2
is a more dynamic regulatory element, with as yet
unconfirmed induction/suppression capacity for PAG1.
To become regulatory active, PRE2 might require, for
example, the presence of signals from PRE3 (e.g., PRE2
might suppress PRE3), appropriate cellular activation
(e.g., allergen or viral stimulation), or transcription factorsFigure 4. Binding of the Foxo3a Tran-
scription Factor to PRE3 Is Disrupted by
the rs2370615:C Allele
Chromatin immunoprecipitation was per-
formed as previously described.39 LCLs
(1 3 107) with the indicated genotypes
were crosslinked, sonicated, and immu-
noprecipitated with either anti-Foxo3a
antibody or control IgG antibody. Immu-
noprecipitates were washed and DNA was
extracted after reverse-crosslinking. The
enrichment of Foxo3a binding to PRE3
(A) and control region 4 kb upstream of
PRE3 (B) was examined by performing
qPCR. The binding of Foxo3a is shown as
fold enrichment over IgG (horizontal
line). Graphs represent three independent
experiments assayed in triplicate. Error
bars denote 95% CI and p values were
determined by unpaired t test.
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Figure 5. The Association between FOXO3A and PAG1 Expression in LCLs Is Modulated by rs2370615 Genotype
Gene expression levels were normalized via a rank-based transformation and adjusted for potential confounders (including ancestry and
16 principal components that capture the effects of unobserved technical confounders on gene expression) and the association tested by
linear regression. Horizontal solid lines show the mean expression of PAG1 for a given genotype class (cf. Figure S1).that have low/no expression in the LCL tested. (3) Individ-
uals with the rs2370615:C allergy risk allele at PRE3 have
overall higher PAG1 expression, perhaps because TFs
such as RelA are able to bind to PRE3 and drive high levels
of PAG1 transcription (Figure S6A). (4) Individuals with the
rs2370615:T allergy protective allele at PRE3 have overall
lower PAG1 expression, perhaps because Foxo3a binds
to PRE3 and drives lower levels of transcription (when
compared to for example RelA) and/or because PRE2,
which physically interacts with the PAG1 promoter
in these individuals, might suppress PRE3 activity
(Figure S6B). Further studies that characterize in greater
detail the molecular mechanisms underlying the regula-
tion of PAG1 expression by PRE2 and PRE3 are warranted.
Importantly, our results suggest that increased PAG1
transcription is associated with increased risk of allergic
disease. To our knowledge, there are no published studies
investigating the contribution of PAG1 to the pathophysi-
ology of allergic diseases. PAG1 encodes the phosphopro-
tein associated with glycosphingolipid microdomains
(or Csk-binding protein, Cbp), a transmembrane adaptor
protein localized to lipid rafts that has highest expression
in the immune system, notably in T and B cells.30–32 One
of the main cellular functions of PAG1 is the regulation
of Csk activity,30 with direct effects on immunoreceptor
signaling.33 The role of PAG1 in the development of
immune responses has been studied extensively using
in vitro and in vivo experimental systems, with conflicting
results (reviewed in Hrdinka and Horejsi33). In brief,
in vitro studies suggest that PAG1 overexpression inhibits
T cell, B cell, and mast cell activation7–10,34 and so, by
extension, would be expected to have an anti-inflamma-
tory effect. In contrast, in vivo studies have shown that
T and B cell development and function are normal in
Pag1-deficient mice.35,36
Our finding that allergy predisposing alleles increase the
transcription of PAG1 in human B cell lines is not consis-
tent with results from these experimental studies; instead,
it suggests that PAG1 overexpression might promote B cell
activation and so have a pro-inflammatory effect. Interest-334 The American Journal of Human Genetics 97, 329–336, August 6ingly, this possibility was proposed by Hrdinka and
Horejsi33 to explain the observation that PAG1 is phos-
phorylated upon antigen stimulation in B cells but not
T cells. This notion is also supported by the recent observa-
tion that PAG1 inhibition in mast cells can suppress
degranulation and the production of pro-inflammatory
cytokines if cells are activated via an allergen-dependent
mechanism.37 Given the potential role of the NF-kB
pathway in PAG1 transcription and the observation that
this pathway is activated by allergen and/or pathogen
engagement of Toll-like receptors,38 characterization of
the immune response to allergen or viral challenge in
Pag1-deficient mice might help resolve the conflicting
observations reported in experimental studies.
A limitation of our work is that we cannot exclude the
possibility that other genes in the region are also targets of
the same variants. We focused our experimental work on
PAG1 because this was the only gene for which we found
a significant association between allergy risk SNPs and vari-
ation in gene expression levels. However, it is possible that
despite no current available eQTL evidence, the expression
of genes such as ZBTB10 or TPD52, which are expressed in
relevant immune cells, might also be regulated by the PREs
we identified, perhaps in different cell types.
In conclusion, we showed that an allergy risk allele on
chromosome 8q21 increases PAG1 transcription by acti-
vating a poised enhancer located 732 kb away from the
gene promoter. The significance of these results is two-
fold. First, they highlight the fact that the target gene(s)
underlying an observed genetic association can be a
considerable distance away from the GWAS sentinel SNP.
Second, our results suggest that inhibition of PAG1 expres-
sion or function might have therapeutic potential to treat
allergic diseases.Supplemental Data
Supplemental Data include six figures and eight tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2015.06.010., 2015
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